Primary endpoint of preventing delayed CINV met with high significance
Cambridge, UK – 6th May 2015: Acacia Pharma Ltd (“Acacia Pharma” or “the Company”), a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).
Niemann-Pick Disease experts Drs. Paul Gissen, Marc Patterson and Forbes D. Porter, along with biopharmaceutical industry leader Dr. Cristina Csimma, join Vtesse in quest to develop new treatments for people facing Niemann-Pick Disease Type C and rare diseases
GAITHERSBURG, Md., March 25, 2015 /PRNewswire/ -- Vtesse, Inc., a rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe diseases with great unmet need, announced today the formation of its Scientific Advisory Board (SAB). Comprising experts from a range of fields including pediatrics, translational medicine, biomarker research and genetics, the SAB will advise on clinical and regulatory strategy as well as product development for the company's lead candidate, VTS-270.
|Forrige Forrige 10 11 12 13 14 15 16 17 18 19 20 Næste 10 Næste|